our history from 1965 till now


Pharmacosmos was established in 1965 by Henry Christensen MD, PhD, who was succeeded by his youngest son Lars Christensen, MD, as CEO in 1993. The company has since its establishment remained an independent family owned company.

The first 500 m2 manufacturing site - site Viby - was established in 1965 in a former dairy in a small village about 40 kilometres from the current site Holbaek. The original manufacturing site was expanded to approximately 1800 m2 in 1973.

Originally, the company was an API manufacturer of dextran powder of clinical grade, pharmacopoieal quality for production of infusion solutions and iron complexes. The API was and is still available in powder and/or bulk solutions for the manufacturing of veterinary iron dextran injection.

The company gained GMP approval from Danish Ministry of Health early-on, followed by a number of US FDA approvals after a 1983 US FDA inspection carried out by Mr Charles A. Wayne.

2016

Pivotal studies for FDA registration

Head-to-Head study of risk of serious hypersensitivity with Monofer® versus iron sucrose in 3,000 patients with IDA

Read more Read less

First ever hard endpoint Trial with IV iron

Investigator lead landmark study in 1,300 patients with CHF and ID supported by the British Heart Foundation and Pharmacosmos

Read more Read less
2015

Introduction of DEAE-Dextran

DEAE-Dextran is used for a number of applications hereunder as vaccine adjuvant, in gene therapy, and protein stabilization

Read more Read less

Pharmacosmos 50th Anniversary

On the 18th of June 2015 Pharmacosmos celebrated its 50 years anniversary

Read more Read less
2014

Expansion of site Holbaek

500 m2 Expansion of site Holbaek - synthesis of derivatives (DEAE and others). Read more

Read more Read less
2013

Diafer® approved

Diafer® regulatory approval and launch

Read more Read less
2011

Uniferon® FDA approved

FDA approval of 10% and 20% Uniferon® in the US

Read more Read less
2009

Expansion in Holbaek

1500 m2 expansion of the site in Holbaek

Read more Read less

Fully integrated pharmaceutical company

Establishment of own Clinical Research and Medical Affairs departments

Read more Read less

Approval of Monofer®

Regulatory approval of Monofer® in 22 EU countries

Read more Read less
2008

Registration of Uniferon®

Registration of Uniferon® in EU and Asia

Read more Read less
2006

Launch of dextran

Launch of dextran in "small-pack" units with focus on broad dextran applications

Read more Read less
2004

Amersham Biosciences

Take over of clinical grade dextran supply from Amersham Biosciences

Read more Read less
2003

Danish Medicines Agency

Danish Medicines Agency first inspection in Holbaek

Read more Read less

New manufacturing facility in Holbaek, Denmark

Inauguration of new 13.000 m2 cGMP manufacturing facility in Holbaek, Denmark - initiates transformation from API manufacturer to development and marketing of pharmaceutical specialties

Read more Read less
2000

Cosmofer® launch

Cosmofer® launch in collaboration with EU partners

Read more Read less
1993

Lars Christensen, MD, appointed CEO

Read more Read less
1992

Supply agreement with Abbott

Supply agreement with Abbott and FDA approval for supply of API in the US

Read more Read less
1988

FDA approval

FDA approval of 20% iron dextran bulk solution

Read more Read less
1985

Viby factory

Expansion of the factory in Viby (laboratories)

Read more Read less
1983

FDA approval of 10%

FDA approval of 10% iron dextran bulk solution for veterinary use

Read more Read less
1973

Production of iron dextran

Initiation of iron dextran production

Read more Read less

First plant enlargement in Viby

The original manufacturing site was expanded to approximately 1800 m2 in 1973

Read more Read less
1965

The first manufacturing

The first 500 m2 manufacturing site was established in 1965 in a former dairy in a small village about 40 kilometres from the current site Holbaek

Read more Read less

The beginning

Pharmacosmos was established in 1965 by Henry Christensen MD, PhD, who was succeeded by his youngest son Lars Christensen, MD, as CEO in 1993. The company has since its establishment remained an independent family owned company

Read more Read less

Pharmacosmos

You are now leaving Pharmacosmos.com. The website you are about to visit is intended for UK  & IE Healthcare professionals and members of the public. Do you want to proceed?